The Ligenesis laser knife advances domestic medical-laser adoption

Since the first laser was demonstrated in 1960, medical lasers have expanded from dermatology and ophthalmology into urology, gynaecology, otolaryngology, neurosurgery, oncology and interventional care. A laser knife can shorten procedures, improve precision and reduce bleeding compared with conventional surgical or electrosurgical instruments.

Its clinical effect is based on controlled thermal interaction. By adjusting wavelength, power, energy density and exposure time, clinicians can cut, separate, vaporise, coagulate, stop bleeding or fragment calculi according to the treatment pathway.

China’s medical-laser market continues to grow, although imported systems have historically remained common in major hospitals. Ligenesis reports that its laser knife and Fuhao laser platform are increasingly used by leading tertiary hospitals, demonstrating greater clinical confidence in domestically engineered equipment.

Medical institutions in Luzhou, Kunming, Wuhan, Suzhou, Foshan, Nanning, Xianyang, Xi’an and Zunyi are among the users choosing the Ligenesis laser knife. This adoption is supported by the company’s research team, quality systems, manufacturing discipline and extensive clinical application data.

Ligenesis will continue to pursue the ambition expressed by chief scientist Professor Li Zhengjia: China has the determination and capability to reach and surpass advanced international levels in medical-laser technology.